2. Academic Validation
  3. Biologicals in severe chronic rhinosinusitis with nasal polyps: translation to clinical practice while waiting for head-to-head studies

Biologicals in severe chronic rhinosinusitis with nasal polyps: translation to clinical practice while waiting for head-to-head studies

  • Rhinology. 2023 Jun 1;61(3):283-286. doi: 10.4193/Rhin22.436.
J L Boechat 1,  B Sousa-Pinto 2,  L Delgado 3,  D Silva 4
Affiliations

Affiliations

  • 1 Clinical Immunology Service, Internal Medicine Department, Faculty of Medicine, Universidade Federal Fluminense, Niteroi/RJ, Brazil; Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal; Center for Health Technology and Services Research (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal.
  • 2 Center for Health Technology and Services Research (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal; MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
  • 3 Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal; Center for Health Technology and Services Research (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal;Servico de Imunoalergologia, Centro Hospitalar de São João, E.P.E., Porto, Portugal.
  • 4 Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal; Servico de Imunoalergologia, Centro Hospitalar de Sao Joao, E.P.E., Porto, Portugal; EPIUnit - Institute of Public Health, University of Porto, Laboratory for Integrative and Translational Research in Population Health (ITR), University of Porto, Porto, Portugal.
PMID: 36946510 DOI: 10.4193/Rhin22.436
Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1.0-2.6% of the population (1) and results in relevant direct and indirect costs. Recently, several randomized controlled trials (RCTs) with Type 2-targeting biologicals (anti-IL4Rα, anti-IL5R, anti-IL5 and anti-IgE) opened a new treatment field for patients refractory to first-line treatments (2,3).

Figures
Products